Aeon Biopharma Inc (AEON) Stock Price, Quote & News

Company Profile

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceu...

Industry: Biotechnology

Sector: Healthcare

Phone: 949 354 6499

Website: www.aeonbiopharma.com

Address:

5 Park Plaza, Suite 1750, Irvine, United States

TWITLIEDETECTOR Mar. 21 at 5:09 PM

$AEON purple binder and earnings. they can’t hide much longer.

0 · Reply

TWITLIEDETECTOR Mar. 21 at 5:04 AM

$AEON the lack of liquidity is an issue that they need to fix. it’s the only bad piece. the silence is lovely.

1 · Reply

BryceyBoy Mar. 20 at 1:43 PM

$AEON Im still sticking by this one, it just seems like it makes sense after the last few months of everyone here talking things through. The news is taking WAY longer to be released than we had all expected but what are you going to do you know

1 · Reply

BryceyBoy Mar. 20 at 12:57 PM

$AEON Everyone seems to be losing patience lol. Just stick with it fellas

1 · Reply

TWITLIEDETECTOR Mar. 20 at 4:26 AM

$AEON you will find me at GUTS. i don’t have the GUTS to fully buy a lot of AEON.

0 · Reply

Allf2 Mar. 19 at 2:38 PM

$AEON Nothing happened today just like yesterday Day-1

1 · Reply

TWITLIEDETECTOR Mar. 18 at 10:10 PM

$AEON the silence is at the point of being good. it’s the lack of liquidity that’s bad

0 · Reply

VXRT007 Mar. 18 at 2:09 AM

$AEON very low liquidity...... they need to do something to trigger FOMO!

0 · Reply

Mandi63 Mar. 17 at 2:57 PM

$AEON give me 5.5…

1 · Reply

Allf2 Mar. 17 at 8:35 AM

$AEON Why is there no news?

0 · Reply

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

Dec 19, 2025, 6:00 PM EST - 3 months ago

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

Dec 15, 2025, 4:05 PM EST - 3 months ago

AEON Biopharma Announces Execution of Exchange Agreement with Daewoong

Nov 20, 2025, 8:30 AM EST - 4 months ago

AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling

Nov 14, 2025, 8:30 AM EST - 4 months ago

AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth

Nov 13, 2025, 8:30 AM EST - 4 months ago

AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes

Oct 1, 2025, 8:00 AM EDT - 6 months ago

AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19

Aug 12, 2025, 4:05 PM EDT - 7 months ago

AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update

May 19, 2025, 4:05 PM EDT - 10 months ago

AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025

May 14, 2025, 4:05 PM EDT - 11 months ago

AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 25, 2025, 4:05 PM EDT - 11 months ago

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Apr 21, 2025, 4:05 PM EDT - 11 months ago

AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

Mar 27, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma Announces CEO Transition

Mar 24, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 4, 2025, 8:00 AM EST - 1 year ago

AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference

Feb 24, 2025, 2:00 PM EST - 1 year ago

AEON Biopharma, Inc. Announces Reverse Stock Split

Feb 7, 2025, 4:05 PM EST - 1 year ago

AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Jan 7, 2025, 9:37 AM EST - 1 year ago

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

Jan 3, 2025, 8:02 PM EST - 1 year ago

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering

Nov 13, 2024, 4:05 PM EST - 1 year ago

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Aug 19, 2024, 4:05 PM EDT - 1 year ago

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 12, 2024, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

May 29, 2024, 8:00 AM EDT - 1 year ago

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

May 14, 2024, 4:05 PM EDT - 2 years ago

AEON Biopharma Reports First Quarter 2024 Financial Results

May 9, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Provides Update on Development Pipeline

May 3, 2024, 7:00 AM EDT - 2 years ago

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

Mar 30, 2024, 10:53 PM EDT - 2 years ago

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

Mar 29, 2024, 4:15 PM EDT - 2 years ago

AEON Biopharma Announces Redemption of Public Warrants

Mar 29, 2024, 3:45 PM EDT - 2 years ago

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 19, 2024, 4:30 PM EDT - 2 years ago

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

Mar 19, 2024, 4:29 PM EDT - 2 years ago

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

Jan 18, 2024, 4:05 PM EST - 2 years ago

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

Dec 12, 2023, 8:00 AM EST - 2 years ago

AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine

Nov 13, 2023, 8:15 AM EST - 2 years ago

AEON Biopharma Reports Third Quarter 2023 Financial Results

Oct 19, 2023, 4:05 PM EDT - 2 years ago

AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

Aug 29, 2023, 8:00 AM EDT - 2 years ago

AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®

Aug 24, 2023, 8:00 AM EDT - 2 years ago

AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

Aug 16, 2023, 7:00 AM EDT - 2 years ago

Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma

Jul 24, 2023, 7:00 AM EDT - 2 years ago

AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update

TWITLIEDETECTOR Mar. 21 at 5:09 PM

$AEON purple binder and earnings. they can’t hide much longer.

0 · Reply

TWITLIEDETECTOR Mar. 21 at 5:04 AM

$AEON the lack of liquidity is an issue that they need to fix. it’s the only bad piece. the silence is lovely.

1 · Reply

BryceyBoy Mar. 20 at 1:43 PM

1 · Reply

BryceyBoy Mar. 20 at 12:57 PM

$AEON Everyone seems to be losing patience lol. Just stick with it fellas

1 · Reply

TWITLIEDETECTOR Mar. 20 at 4:26 AM

$AEON you will find me at GUTS. i don’t have the GUTS to fully buy a lot of AEON.

0 · Reply

Allf2 Mar. 19 at 2:38 PM

$AEON Nothing happened today just like yesterday Day-1

1 · Reply

TWITLIEDETECTOR Mar. 18 at 10:10 PM

$AEON the silence is at the point of being good. it’s the lack of liquidity that’s bad

0 · Reply

VXRT007 Mar. 18 at 2:09 AM

$AEON very low liquidity...... they need to do something to trigger FOMO!

0 · Reply

Mandi63 Mar. 17 at 2:57 PM

$AEON give me 5.5…

1 · Reply

Allf2 Mar. 17 at 8:35 AM

$AEON Why is there no news?

0 · Reply

HalEugene Mar. 16 at 1:20 PM

$AEON Investment not a trade.

0 · Reply

TWITLIEDETECTOR Mar. 16 at 5:01 AM

$AEON Posted too much here. you are a boring group. will hold my position but i am moving on to observe some other stocks more closely. i never buy in too fast i study and watch.

1 · Reply

TWITLIEDETECTOR Mar. 14 at 10:45 PM

$AEON consolidation has completely changed resistance. i am no stock expert but this play has changed.

1 · Reply

VinWeezel Mar. 13 at 7:52 PM

$AEON free dorito alerts. Rob Bancroft apparently loves cooler ranch and had a meeting about a new flavor he won’t tell us about.

0 · Reply

Mandi63 Mar. 13 at 6:19 PM

$AEON one a-hole keeps bring this stock down.. please stop..use your skills to move it up..

1 · Reply

Mandi63 Mar. 13 at 2:43 PM

$AEON waiting…i sold a stock years ago for 1.00 something …it layer hit $200…lol would have been a millionaire a few times … management matters..

1 · Reply

TWITLIEDETECTOR Mar. 13 at 4:01 AM

$AEON some of you said there was no dd left to do. perhaps now that is true

0 · Reply

TWITLIEDETECTOR Mar. 11 at 5:51 PM

$AEON 1.09 to the rescue. told you so LOL

1 · Reply

TWITLIEDETECTOR Mar. 11 at 5:09 PM

$AEON has to break 1.22

0 · Reply

VinWeezel Mar. 11 at 4:28 PM

$AEON visions of 1.80.

0 · Reply

TWITLIEDETECTOR Mar. 11 at 2:58 AM

$AEON $1.09 is back. remember why?

2 · Reply

BryceyBoy Mar. 10 at 2:33 PM

$AEON Would be interesting if they released the approval right before they do their presentation.

1 · Reply

Market Cap	13.50M
Revenue (ttm)	0.00
Net Income (ttm)	42.01M
EPS (ttm)	N/A
PE Ratio	0.43
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	64,600
Avg Vol	146,186
Day's Range	N/A - N/A
Shares Out	11.84M
Stochastic %K	11%
Beta	0.72
Analysts	Strong Sell
Price Target	$6.10